224 related articles for article (PubMed ID: 33182316)
1. Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible.
Witzig VS; Komnig D; Falkenburger BH
Cells; 2020 Nov; 9(11):. PubMed ID: 33182316
[TBL] [Abstract][Full Text] [Related]
2. Acute MPTP treatment decreases dendritic spine density of striatal medium spiny neurons via SNK-SPAR pathway in C57BL/6 mice.
Su Y; Jia M; Yuan S; Wang C; Feng J; Zhang Y
Synapse; 2022 Sep; 76(11-12):e22249. PubMed ID: 36008099
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the dendritic structure of the striatal medium spiny neurons accompanies behavioral recovery in a mouse model of Parkinson's disease.
Kim W; Im MJ; Park CH; Lee CJ; Choi S; Yoon BJ
Neurosci Lett; 2013 Dec; 557 Pt B():95-100. PubMed ID: 24176882
[TBL] [Abstract][Full Text] [Related]
4. Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Toy WA; Petzinger GM; Leyshon BJ; Akopian GK; Walsh JP; Hoffman MV; Vučković MG; Jakowec MW
Neurobiol Dis; 2014 Mar; 63():201-9. PubMed ID: 24316165
[TBL] [Abstract][Full Text] [Related]
5. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse.
German DC; Nelson EL; Liang CL; Speciale SG; Sinton CM; Sonsalla PK
Neurodegeneration; 1996 Dec; 5(4):299-312. PubMed ID: 9117541
[TBL] [Abstract][Full Text] [Related]
6. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Garcia BG; Neely MD; Deutch AY
Cereb Cortex; 2010 Oct; 20(10):2423-32. PubMed ID: 20118184
[TBL] [Abstract][Full Text] [Related]
7. Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.
Neely MD; Schmidt DE; Deutch AY
Neuroscience; 2007 Oct; 149(2):457-64. PubMed ID: 17888581
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-independent development and maintenance of mouse striatal medium spiny neuron dendritic spines.
Zhong M; Wang Y; Lin G; Liao FF; Zhou FM
Neurobiol Dis; 2023 Jun; 181():106096. PubMed ID: 37001611
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.
Villalba RM; Lee H; Smith Y
Exp Neurol; 2009 Feb; 215(2):220-7. PubMed ID: 18977221
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
[TBL] [Abstract][Full Text] [Related]
12. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
13. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
14. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
15. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
16. Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation.
Cruz-Sanchez FF; Cardozo A; Ambrosio S; Tolosa E; Mahy N
Mol Chem Neuropathol; 1993; 19(1-2):163-76. PubMed ID: 8103334
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
Wei W; Ding S; Zhou FM
J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
[TBL] [Abstract][Full Text] [Related]
18. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase.
Zhang J; Graham DG; Montine TJ; Ho YS
J Neuropathol Exp Neurol; 2000 Jan; 59(1):53-61. PubMed ID: 10744035
[TBL] [Abstract][Full Text] [Related]
19. Striatal spine plasticity in Parkinson's disease: pathological or not?
Smith Y; Villalba RM; Raju DV
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3(Suppl 3):S156-61. PubMed ID: 20082980
[TBL] [Abstract][Full Text] [Related]
20. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism.
Deutch AY; Colbran RJ; Winder DJ
Parkinsonism Relat Disord; 2007; 13 Suppl 3(Suppl 3):S251-8. PubMed ID: 18267246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
